What is LymeMIND

The Icahn School of Medicine at Mount Sinai is building a multiscale integrated network of Lyme Disease (LymeMIND) that represents a unified, predictive model of Lyme disease

LymeMIND is designed enable a systems medicine approach to identify novel biomarkers and new therapeutic opportunities. Through our network of collaborators, we are able to interrogate the complex biology of samples collected from Lyme-affected individuals using molecular profiling technologies and applying advanced statistical and machine learning approaches to move rapidly from “Big Data” to knowledge and improved understanding of the disease.

Lyme disease, caused by bacteria infected ticks, infects an estimated 300,000 people each year in the United States.

The disease is known to be profoundly complex, involving multiple tissues and organs systems that result in complex interactions between host and pathogen. The natural history of disease is also complex, with acute infection that mimics signs of other illnesses and often leading to chronic neurological, immune, and musculoskeletal dysfunction.

The Icahn School of Medicine at Mount Sinai uses its unique vantage at the nexus of clinical medicine, applied -omics, data science, and digital health to illuminate better understanding, prevention, and treatment of complex diseases.


Contact Us

Icahn School of Medicine at Mount Sinai
770 Lexington Avenue15th FloorNew York, NY 10065212-731-7047lymemind@mssm.edu